Vimarsana
Biggest News Aggregation in the World

Page 3 - Director Division News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Director Division. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Director Division Today - Breaking & Trending Today

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development - Vimarsana News

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

/PRNewswire/ -- TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer's disease (AD), being the only company running late-stage...

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development - Vimarsana News

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

/PRNewswire/ -- TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer's disease (AD), being the only company running late-stage...

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development - Vimarsana News

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

/PRNewswire/ -- TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer's disease (AD), being the only company running late-stage...

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development - Vimarsana News

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco - For people with early Alzheimer's (MCI), HMTM improvement in cognition over pre-treatment baseline now shown to be sustained over 18 months ABERDEEN, Scotland and SINGAPORE, Dec. 1, 2022 /PRNewswire/ --TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alz...

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development - Vimarsana News

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

/PRNewswire/ -- TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer's disease (AD), being the only company running late-stage...